<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359359</url>
  </required_header>
  <id_info>
    <org_study_id>91495</org_study_id>
    <secondary_id>2006-000067-29</secondary_id>
    <secondary_id>310101</secondary_id>
    <nct_id>NCT00359359</nct_id>
  </id_info>
  <brief_title>A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the study drug ZK 219477 (also known as SH
      Y03757A) combined with cisplatin, is effective in the treatment of small cell lung cancer in
      patients who did not receive prior treatment for their lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor
      of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety measure to establish the MTD or RPDII dose of Sagopilone used in combination with cisplatin</measure>
    <time_frame>Phase 1: Baseline up to 3 month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Efficacy measure</measure>
    <time_frame>Phase 2: every 6 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: PK of Sagopilone + Cisplatin</measure>
    <time_frame>Upto 336 h after the beginning of the sagopilone infusion and upto 20 h 45 min after the beginning of the cisplatin infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of CR or PR</measure>
    <time_frame>every 6 weeks after start of treatment</time_frame>
    <description>Duration of complete response (CR) or partial response (PR) as 'overall response', defined as time between first date that the measurement criteria for CR or PR as 'overall response' are met and first date that recurrence or overall response of (progressive disease) PD is documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: TTP</measure>
    <time_frame>every 6 weeks after start of treatment</time_frame>
    <description>Time to tumor progression (TTP) is defined as the time from the date of treatment assignment to the first observation of disease progression or to the last date of a definite assessment (not status unknown), if the patient is progression-free until that assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: PFS</measure>
    <time_frame>every 6 weeks after start of treatment</time_frame>
    <description>Progression free survival (PFS) is defined as the time from date of treatment assignment to the first observation of disease progression or death of any cause or to the last date of a definite assessment (not status unknown), if the patient was progression-free until that assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: OS</measure>
    <time_frame>every 3 months after start of treatment</time_frame>
    <description>Overall survival (OS) is defined as the time from date of treatment assignment until death from any cause or until the last date the patient is known to be alive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <arm_group>
    <arm_group_label>Sagopilone and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug sagopilone was administered in combination with a fixed dose of cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sagopilone (BAY86-5302, ZK 219477)</intervention_name>
    <description>Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID</description>
    <arm_group_label>Sagopilone and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1</description>
    <arm_group_label>Sagopilone and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Small-cell lung cancer

          -  Stage of extensive disease

          -  Adequate function of major organs and systems

          -  Use of highly effective birth control methods in females of child-bearing potential

        Exclusion Criteria:

          -  Prior chemotherapy for small-cell lung cancer

          -  Prior surgical resection or radiotherapy for SCLC within at least 3 to 4 weeks prior
             to inclusion and with the exception of radiation of brain metastases

          -  Superior vena cava syndrome or obstruction of any vital structure

          -  Untreated malignant hypercalcemia; Extensive disease amenable to radiation therapy;
             Symptomatic brain metastases requiring whole-brain irradiation

          -  Known allergy or hypersensitivity to platinum-containing drugs

          -  Pregnancy or breast-feeding

          -  Use of any investigational drug within 4 weeks before start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gerlingen</city>
        <state>Baden-Württemberg</state>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Löwenstein</city>
        <state>Baden-Württemberg</state>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2006</study_first_submitted>
  <study_first_submitted_qc>August 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2006</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

